Cost effectiveness of interferon-gamma release assay versus chest X-ray for tuberculosis screening of BCG-vaccinated elderly populations

Molecular Diagnosis and Therapy

Volumn 14, Issue 4, 2010, Pages 229-236

  Kowada, Akiko ^a   Deshpande, Gautam A ^b   Takahashi, Osamu ^c   Shimbo, Takuro ^d   Fukui, Tsuguya ^c  

^a Bunkyo City Public Health Center   (Japan)

^b UNIVERSITY OF HAWAII   (United States)

^c ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^d Clinical Research Center   (Japan)

Author keywords

Cost effectiveness; Diagnostic Screening; Diagnostic Tests; Elderly; Radiography; Tuberculosis, diagnosis

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; ISONIAZID;

AGED; ARTICLE; BCG VACCINATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; IMMUNOCOMPETENCE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SCREENING; THORAX RADIOGRAPHY;

EID: 77956261729     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/bf03256378     Document Type: Article

References (26)

1. Ohmori M. Probability of having latent tuberculosis infection in Japan [in Japanese]. Tokyo: Research Institute of Tuberculosis, 2009 May [online]. Available from URL: http://jata.or.jp/rit/ekigaku/[Accessed 2010 Feb 14]
2. Berrington de Gonzalez A, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 2004; 363: 345-351
3. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008 Aug 5; 149 (3): 177-184
4. Diel R, Schaberg T, Loddenkemper R, et al. Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany. Respir Med 2009 Dec; 103 (12): 1838-1853
5. Hardy AB, Varma R, Collyns T, et al. Cost-effectiveness of the NICE guide-lines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries. Thorax 2010 Feb; 65 (2): 178-180
6. Kowada A, Takahashi O, Shimbo T, et al. Cost effectiveness of interferon-gamma release assay for tuberculosis contact screening in Japan. Mol Diagn Ther 2008; 12 (4): 235-251
7. Tuberculosis Research Committee (Ryoken). Relapse rate of tuberculosis treated with standard regimen of chemotherapy [in Japanese]. Kekkaku 2009; 84: 617-625
8. Horsburgh Jr CR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350 (20): 2060-2067
9. Yoshiyama T. Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings. Kekkaku 2000; 75 (11): 629-641
10. Stead WW, To T, Harrison RW, et al. Benefit-risk considerations in preventive therapy for tuberculosis in elderly persons. Ann Intern Med 1987; 107 (6): 843-845
11. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations ofisoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-564
12. Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid hepatotoxicity asso-ciated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005; 128 (1): 116-123
13. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168 (4): 443-447
14. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of com-mercial interferon-gamma release assays for detecting active TB: a meta-analysis. Chest 2010; 137: 952-968
15. Dasgupta K, Menzies D. Cost-effectiveness of tuberculosis control strategies among immigrants and refugees. Eur Respir J 2005; 25: 1107-1116
16. Diel R, Nienhaus A, Schaberg T. Cost-effectiveness of isoniazid chemo-prevention in close contacts. Eur Respir J 2005; 26 (3): 465-473
17. Statistics Bureau, Ministry of Internal Affairs and Communications. Life ta-bles, 2005. Tokyo: Statistics Bureau, 2008 [online]. Available from URL: http://www.stat.go.jp/english/index/official/202.htm [Accessed 2010 Feb 20]
18. Ferrara G, Losi M, D'Amico R, et al. Interferon-gamma-release assays detect recent tuberculosis re-infection in elderly contacts. Int J Immunopathol Pharmacol 2009 Jul-Sep; 22 (3): 669-677
19. Salpeter S, Sanders G, Salpeter E, et al. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years ofage: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997; 127: 1051-1061
20. Tuberculosis Research Committee. Drug-resistant Mycobacterium tuberculosis in Japan: a nationwide survey, 2002. Int J Tuberc Lung Dis 2007; 11: 1129-1135
21. Organization for Economic Co-Operation and Development. PPPs for GDP-historical series. Paris: Organization for Economic Co-Operation and Development 2008 [online]. Available from URL: http//www.oecd.org/data oecd/61/56/39653523.xls [Accessed 2010 Jul 22]
22. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis 2007 Jan; 11 (1): 16-26
23. Pai M, O'Brien R. serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions? PLoS Med 2007 Jun; 4 (6): e208
24. Beffa P, Zellweger A, Janssens JP, et al. Indeterminate test results of T-SPOT.TB performed under routine field conditions. Eur Respir J 2008; 31: 842-846
25. Lee SW, Jang YS, Park CM, et al. The role of chest CT scanning in tuberculosis outbreak investigation. Chest 2010; 137: 1057-1064
26. Lew WJ, Jung YJ, Song JW, et al. Combined use of QuantiFERON-TB Gold assay and chest computed tomography in a tuberculosis outbreak. Int J Tu-berc Lung Dis 2009 May; 13 (5): 633-639